Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.56 |
| ▸ | BRD2 | P25440 | 9/20 | 0.56 |
| ▸ | BRD3 | Q15059 | 8/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | EDNRB | P24530 | 3/20 | 0.44 |
| ▸ | EDNRA | P25101 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569878 | 0.88 | BRD4 (0.50) | BRD4BRD2BRD3CREBBPNPSR1 | |
| SCHEMBL13552627 | 0.85 | BRD4 (0.48) | BRD4BRD2BRD3CREBBPEDNRB | |
| SCHEMBL4569890 | 0.80 | EDNRA (0.45) | BRD4BRD2BRD3EDNRBEDNRA | |
| SCHEMBL4572266 | 0.80 | BRD4 (0.43) | BRD4BRD2BRD3CREBBPEDNRB | |
| SCHEMBL4569883 | 0.79 | NPSR1 (0.50) | NPSR1KDM4ERXFP1ACLY | |
| SCHEMBL4572287 | 0.78 | NRP1 (0.54) | BRD4BRD2BRD3 | |
| SCHEMBL4569912 | 0.77 | NRP1 (0.54) | BRD4BRD2BRD3 | |
| SCHEMBL4569879 | 0.76 | NRP1 (0.47) | BRD4BRD2BRD3 | |
| SCHEMBL2747710 | 0.76 | ACLY (0.59) | NPSR1KDM4ERXFP1ACLY | |
| SCHEMBL4569886 | 0.75 | TRIM24 (0.49) | BRD4CREBBPNPSR1KDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| US-8158789-B2 | Arginine derivatives with NP-I antagonistic activity | Ark Therapeutics Group Ltd. (GB) | 2012-04-17 | — | — | US | disclosed |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | BRD4 2083/4885BRD2 2089/4885BRD3 2668/4885 |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | BRD4 2083/4885BRD2 2089/4885BRD3 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.